Drug
Lapiteronel clinical trials
Also written CFG920.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Laekna Limited (2) · Novartis Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lapiteronel is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate CancerTerminatedPhase 1/2Laekna LimitedNCT03843918Written as LAE001
- Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPCCompletedPhase 1/2Laekna LimitedNCT04060394Written as Phase I and Phase II: LAE001/prednisone + afuresertib
- A Study of Oral CFG920 in Patients With Castration Resistant Prostate CancerTerminatedPhase 1Novartis PharmaceuticalsNCT01647789Written as CFG920
Codes
What other systems call lapiteronel · ClinicalTrials.gg INT018154
- UNII (FDA) UP0K5026VBLAPITERONELOne source FDA
- NCI Thesaurus C102855LapiteronelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UP0K5026VB | LAPITERONEL | One source FDA |
| NCI Thesaurus | C102855 | Lapiteronel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.